Novo Nordisk sees solid Q1 results, major GLP-1 growth potential, and limited downside despite guidance cut and rising risks.

On June 23, Eli Lilly and Company (NYSE:LLY) declared a quarterly dividend of $1.50 per share, which was in line with its ...

Eli Lilly and Company (NYSE:LLY) is one of the high-margin pharma stocks to buy now. Eli Lilly and Company (NYSE:LLY) is set ...

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a ...

It’s time we stop creating work that holds up a mirror to what’s broken and start imagining creative solutions that inspire a ...

Finally, don't discount legal challenges to the president's tariffs. An argument could be made that pharmaceutical products ...

Company touted Kisqali's "replacement power" as another blockbuster faces generic competition and expressed optimism about ...

We said to buy shares in early July 2024, when the stock had gotten knocked down to $192. The market was concerned a new Eli Lilly pill would reduce patients’ obstructive sleep apnea, or OSA, enough ...

Johnson & Johnson shares jumped to their highest price in more than three months as the US-based healthcare group shrugged ...

Eli Lilly’s stock closed at $771.75, slipping 3.45% and lagging the broader market. The company’s shares fell despite ...

Detailed price information for Verve Therapeutics Inc (VERV-Q) from The Globe and Mail including charting and trades.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.